Aldeyra Therapeutics, Inc (NASDAQ:ALDX) shares were up 2.2% during mid-day trading on Wednesday . The stock traded as high as $5.64 and last traded at $5.70, approximately 27,456 shares were traded during trading. A decline of 78% from the average daily volume of 126,187 shares. The stock had previously closed at $5.58.

Several research firms recently issued reports on ALDX. Cantor Fitzgerald set a $33.00 price target on Aldeyra Therapeutics and gave the company a “buy” rating in a report on Tuesday, June 25th. ValuEngine raised Aldeyra Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday. Finally, Zacks Investment Research downgraded shares of Aldeyra Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 14th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Aldeyra Therapeutics currently has an average rating of “Buy” and a consensus target price of $26.79.

The business’s fifty day simple moving average is $5.04 and its 200 day simple moving average is $6.82. The stock has a market cap of $153.90 million, a price-to-earnings ratio of -3.30 and a beta of 0.61.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.02. On average, sell-side analysts forecast that Aldeyra Therapeutics, Inc will post -2.01 EPS for the current year.

Several large investors have recently bought and sold shares of the company. Bank of America Corp DE increased its holdings in Aldeyra Therapeutics by 139.4% in the fourth quarter. Bank of America Corp DE now owns 12,181 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 7,093 shares during the last quarter. Deutsche Bank AG boosted its holdings in Aldeyra Therapeutics by 17.0% during the fourth quarter. Deutsche Bank AG now owns 39,658 shares of the biotechnology company’s stock worth $328,000 after buying an additional 5,753 shares during the last quarter. BNP Paribas Arbitrage SA bought a new position in Aldeyra Therapeutics during the first quarter worth about $40,000. Rhumbline Advisers grew its position in shares of Aldeyra Therapeutics by 17.3% during the 1st quarter. Rhumbline Advisers now owns 27,183 shares of the biotechnology company’s stock worth $245,000 after buying an additional 4,010 shares during the period. Finally, National Asset Management Inc. grew its position in shares of Aldeyra Therapeutics by 69.4% during the 1st quarter. National Asset Management Inc. now owns 27,006 shares of the biotechnology company’s stock worth $244,000 after buying an additional 11,066 shares during the period. Institutional investors and hedge funds own 61.26% of the company’s stock.

Aldeyra Therapeutics Company Profile (NASDAQ:ALDX)

Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.

Featured Article: Purposes and Functions of the Federal Reserve

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.